Here's Why This Dividend King Is a Buy for Income Investors
During a market correction, sometimes even the highest quality blue-chip stocks can be hit hard. With its stock falling 23% so far this year, Abbott Laboratories (NYSE: ABT) is a fitting recent example. Compared to the S&P 500 index's 20% year-to-date decline, Abbott Laboratories' drop has been a little more pronounced.
But this sell-off appears to have created a buying opportunity for yield-hungry investors. Let's dive into Abbott Laboratories' fundamentals and valuation to find out why.
Image source: Getty Images.
Source Fool.com
